Chiyoda Corporation is pleased to announce that it has been awarded an Engineering, Procurement and Construction (EPC) contract by AGC Corporation (AGC) for a new biopharmaceutical API manufacturing plant at the AGC Yokohama Technical Center, Tsurumi-ku, Yokohama.
Chiyoda has been awarded the contract as part of AGC’s expansion and development of their manufacturing network as a global biopharmaceutical CDMO.
The project has been selected by the Japanese Ministry of Economy, Trade and Industry (METI) as part of its ‘Development of biopharmaceutical manufacturing sites to Strengthen Vaccine Production’ program. The new plant will house additional mammalian cell culture bioreactors, making it one of the largest sites for mammalian-based manufacturing in Japan, will include facilities in the leading-edge field of mRNA pharmaceuticals and gene and cell therapies and will introduce dual-use facilities that can manufacture vaccines in the event of a pandemic
As one of Chiyoda’s four new business domains, its life sciences business contributes to society’s health and safety and is rapidly increasing in importance due to the changing needs of the bioindustry.
Through the execution of this project supporting the development of domestic biopharmaceutical manufacturing capabilities which currently rely on overseas CDMOs, Chiyoda continues contributing to the realization of a sustainable society in line with our purpose of ‘Enriching Society through Engineering Value’
Source: Chiyoda Corporation